Who is the sponsor?
EyeTech Pharmaceuticals(Now OSI Pharmaceuticals)
Who are the patients?
Male or female over the age of fifty years with AMD The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.
How long are the eligible patients enrollment?
One year. Patients have a random chance of continuing for a second year.
When did participation agreement start at our site?
April 4, 2001
What is the enrollment goal for the sponsor?
Five hundred and forty nationwide.
Is the enrollment still open?
No. This study is now closed.
What is this study investigating?
Abnornal VEGF (vascular endothelial growth factor) production may be contributing to the pathology of neovascular(abnormal new vessel growth) AMD. MacugenTM is a PEGylated anti-VEGF aptamer. The aim of using an anti-VEGF aptamer for treating neovascular AMD is to neutralize VEGF in the eye by binding to VEGF and preventing it from binding into its receptor, there by mitigating the abnormal growth of blood vessels.
How is the treatment administered?